CVD in RA SIGNED
Mechanistic links between rheumatoid arthritis and cardiovascular complications: investigation on inflammation induced alterations in induced pluripotent stem cell-derived cardiomyocytes
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0CVD in RA project word cloud
Explore the words cloud of the CVD in RA project. It provides you a very rough idea of what is the project "CVD in RA" about.
Project "CVD in RA" data sheet
The following table provides information about the project.
| Coordinator |
SLASKI PARK TECHNOLOGII MEDYCZNYCH KARDIO-MED SILESIA SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
Organization address contact info |
| Coordinator Country | Poland [PL] |
| Total cost | 149˙625 € |
| EC max contribution | 149˙625 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2018 |
| Funding Scheme | MSCA-IF-EF-ST |
| Starting year | 2020 |
| Duration (year-month-day) | from 2020-04-01 to 2022-03-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | SLASKI PARK TECHNOLOGII MEDYCZNYCH KARDIO-MED SILESIA SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA | PL (ZABRZE) | coordinator | 149˙625.00 |
Map
Project objective
The aim of this project is to uncover the mechanisms by which patients with rheumatoid arthritis (RA) may have an elevated risk of cardiovascular complications. In particular, we will determine the role of the inflamed joint microenvironment in promoting cellular bioenergetics of cardiomyocytes. We aim to test the hypothesis that cardiomyocytes of RA patients reflect the features of pathological changes that might indicate for the cardiac vulnerability characteristic for this disease. This proposal has three specific objectives: (1) To examine whether exposure of control and RA-specific induced pluripotent stem cells-derived cardiomyocytes (RA-iPSC-CMs) into a joint-like environment recapitulate a cardiac disease-like state; (2) to determine the effect of a joint-like environment on cellular bioenergetics of control and RA-iPSC-derived CMs; and (3) to test whether control and RA-iPSC-CMs can act as a tool to identify potential cardioprotective/cardiotoxic treatment strategies used in RA.
This project proposes a truly translational, bench-to-bedside approach building on the strength of the human RA model. We will establish a unique source of functional cardiomyocytes by reprogramming RA synovial fibroblasts and peripheral blood mononuclear cells to iPSC. To investigate the impact of the joint inflammation on cardiomyocytes’ bioenergetics and transcriptomic profile, the state-of-the-art technologies will be applied. The most advanced cell metabolism analyser will be used to quantify real-time measurements of mitochondrial respiration and glycolysis. Global analysis of mRNA and miRNA transcriptome by RNA-seq will allow identifying new cardiomyocyte-specific genes/pathways that might affect cellular metabolism in RA.
Using iPSC-CMs will provide a unique opportunity to examine the pathophysiology of cardiac involvement in RA and to evaluate whether they may serve as a preclinical platform for precision medicine.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CVD IN RA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CVD IN RA" are provided by the European Opendata Portal: CORDIS opendata.